Xilio Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 76

Employees

  • Stock Symbol
  • XLO

Stock Symbol

  • Share Price
  • $8.07
  • (As of Friday Closing)

Xilio Therapeutics General Information

Description

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Contact Information

Website
www.xiliotx.com
Formerly Known As
Akrevia Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 828 Winter Street
  • Suite 300
  • Waltham, MA 02451
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 828 Winter Street
  • Suite 300
  • Waltham, MA 02451
  • United States
+1 (857)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xilio Therapeutics Stock Performance

As of 13-Nov-2026, Xilio Therapeutics’s stock price is $8.07. Its current market cap is $57M with 7.06M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.07 $8.24 $6.47 - $11.30 $57M 7.06M 12.1K -$0.22

Xilio Therapeutics Financials Summary

As of 30-Sep-2026, Xilio Therapeutics has a trailing 12-month revenue of $55M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (70,187) (62,890) (9,183) (30,238)
Revenue 55,010 43,766 6,344 0
EBITDA (10,171) (33,495) (56,597) (74,504)
Net Income (11,490) (35,036) (58,241) (76,404)
Total Assets 134,832 154,685 71,075 60,926
Total Debt 5,960 6,954 8,142 12,504
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Xilio Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xilio Therapeutics‘s full profile, request access.

Request a free trial

Xilio Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Xilio Therapeutics‘s full profile, request access.

Request a free trial

Xilio Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-onc
Drug Discovery
Waltham, MA
76 As of 2026

Waltham, MA
 

Somerville, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xilio Therapeutics Competitors (2)

One of Xilio Therapeutics’s 2 competitors is Werewolf Therapeutics, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Werewolf Therapeutics Formerly VC-backed Waltham, MA
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
You’re viewing 2 of 2 competitors. Get the full list »

Xilio Therapeutics Patents

Xilio Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020139920-A2 Activatable masked anti-ctla4 binding proteins Inactive 26-Dec-2018
WO-2020139920-A3 Activatable masked anti-ctla4 binding proteins Inactive 26-Dec-2018
WO-2020139926-A2 Anti-ctla4 antibodies and methods of use thereof Inactive 26-Dec-2018
WO-2020139926-A3 Anti-ctla4 antibodies and methods of use thereof Inactive 26-Dec-2018
WO-2020069398-A1 Masked cytokine polypeptides Inactive 27-Sep-2018 C07K14/55
To view Xilio Therapeutics’s complete patent history, request access »

Xilio Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xilio Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xilio Therapeutics‘s full profile, request access.

Request a free trial

Xilio Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.23 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Xilio Therapeutics’s complete esg history, request access »

Xilio Therapeutics FAQs

  • When was Xilio Therapeutics founded?

    Xilio Therapeutics was founded in 2016.

  • Where is Xilio Therapeutics headquartered?

    Xilio Therapeutics is headquartered in Waltham, MA.

  • What is the size of Xilio Therapeutics?

    Xilio Therapeutics has 76 total employees.

  • What industry is Xilio Therapeutics in?

    Xilio Therapeutics’s primary industry is Drug Discovery.

  • Is Xilio Therapeutics a private or public company?

    Xilio Therapeutics is a Public company.

  • What is Xilio Therapeutics’s stock symbol?

    The ticker symbol for Xilio Therapeutics is XLO.

  • What is the current stock price of Xilio Therapeutics?

    As of 13-Nov-2026 the stock price of Xilio Therapeutics is $8.07.

  • What is the current market cap of Xilio Therapeutics?

    The current market capitalization of Xilio Therapeutics is $57M.

  • What is Xilio Therapeutics’s current revenue?

    The trailing twelve month revenue for Xilio Therapeutics is $55M.

  • Who are Xilio Therapeutics’s competitors?

    Werewolf Therapeutics and Genetix Biotherapeutics are competitors of Xilio Therapeutics.

  • What is Xilio Therapeutics’s annual earnings per share (EPS)?

    Xilio Therapeutics’s EPS for 12 months was -$0.22.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process